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Abstract
Background: Predictors of treatment outcome were eval-
uated in a clinical sample suffering from hypochondria-
sis. Methods: The sample consisted of 96 patients with
hypochondriacal disorder according to DSM-IV or high
syndrome scores on the Illness Attitude Scales (IAS) or
Whiteley Index (WI). After intense inpatient cognitive-
behavioral treatment (CBT), 60% of the patients were
classified as responders because of substantial improve-
ments or recovery from hypochondriacal symptomatolo-
gy. Results: Non-responders were characterized by a
higher degree of pre-treatment hypochondriasis, more
somatization symptoms and general psychopathology
(SCL-90R), more dysfunctional cognitions related to
bodily functioning, higher levels of psychosocial impair-
ments, and more utilization of the health care system as
indicated by the number of hospital days and costs for
inpatient treatments and medication. No predictive value
was found for sociodemographic variables, comorbidity
with other mental disorders and chronicity. Multiple
linear regression showed that pre-treatment variables
significantly predicted IAS scores at post-treatment (R2 =
0.59), changes during treatment (0.10), IAS scores at fol-
low-up two years later (0.41) and changes between base-
line and follow-up (0.25). Conclusions: The results dem-
onstrate the relevance of various psychopathological
variables and health care utilization as important indica-
tors for outcome and further course of clinical hypochon-
driasis.
Copyright © 2002 S. Karger AG, Basel
Hypochondriasis is a traditional diagnosis related to
health anxieties and perceived disturbances of bodily
functioning. According to modern nosology, hypochon-
driacal patients are considered as somatoform because
most of them suffer from somatic complaints for which no
organic reasons can be found [1]. The health anxieties
may dominate the clinical picture either alone or second-
ary to other symptomatology such as depressive or anxi-
ety disorders [2, 3]. The exact etiology of hypochondriasis
is not known. Some findings suggest that misinterpreta-
tions of benign bodily symptoms as signs of a serious dis-
ease play an important role [4, 5]. Hypochondriacal
patients show selective attention towards even minor sen-
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sations in their body, are over-concerned with their physi-
cal functioning, and habituate less to somatosensory input
[6]. Illness behaviors such as doctor shopping and excess
utilization of health care are considered as maintenance
factors [7], frequently associated with widespread impair-
ments in psychosocial functioning [8]. Many of these fac-
tors seem to interact in complex ways, as recently outlined
by Fava and Sonino [9] for clinical conditions in the field
of psychosomatic medicine.
Little is known about the natural course of hypochon-
driacal disorder. Episodes of transient hypochondriasis
seem to be a common phenomenon of everyday life [10]
and are frequently observed in general medical patients
[11]. However, severe health anxieties may also persist
over long periods of time. The DSM-IV diagnosis of hypo-
chondriasis requires a minimum duration of six months.
Robbins and Kirmayer [12] differentiated between tran-
sient, emerging and persistent hypochondriasis in a one-
year follow-up study of hypochondriacal patients. They
found that the strongest predictors for persistent hypo-
chondriasis were comorbid depressive or anxiety disor-
ders, fears of emotional instability, pathological symptom
attributions and interpersonal vulnerability.
Facing the severe distress and disabilities of hypochon-
driacal patients, treatment strategies were developed for
this clinical group based on cognitive-behavioral theory.
Body-related cognitive dysfunctions and associated ill-
ness behaviors are taken into account by interventions
such as those described by Bouman and Visser [13] or
Warwick and Salkovskis [14]. They aim at interrupting
the vicious circle of selective attention and misinterpreta-
tion, health anxieties, maladaptive behaviors in the medi-
cal system, psychopathology and psychosocial impair-
ments. The effectiveness of cognitive-behavioral therapy
(CBT) for hypochondriacal patients has been demon-
strated in different clinical and controlled studies [15–
18].
Data about more long-standing effects of CBT are
available only for the heterogeneous group of somatoform
disorders and not specifically for hypochondriasis. Rief et
al. [19] reported that 27% of patients were in remission
two years after inpatient CBT. Prognosis was better when
the somatoform disorder had not been complicated by
comorbid depressive or anxiety disorders. Speckens et al.
[20] found higher remission rates, lower symptom intensi-
ty and less functional impairment in terms of social inter-
actions and illness behavior in general medical outpa-
tients one year after outpatient CBT, as compared to
patients who had received optimized medical care.
Despite these encouraging results, almost nothing is
known about factors predicting response and long-term
outcome of CBT. It has not yet been evaluated which
patients are responders and which fail to have treatment
success. The only predictor study known to us is the one
by Speckens et al. [21] who found that dimensional scores
of hypochondriasis were negatively related with recovery
one year later, illness behavior scores were predictive of
the number of visits to the general practitioner, and hypo-
chondriacal patients had less remission than somatizing
patients without hypochondriasis. However, the sample
described by these authors had only received clinical care
and not CBT, and the strength of prediction was not
directly analyzed because outcome was categorized and
only ß-weights of linear regression were reported.
We conducted a prospective study to evaluate which
factors influence treatment effects and predict the clinical
status immediately after treatment and two years later.
The methodological aims of the study were (1) to differen-
tiate between responders and non-responders of inpatient
CBT for hypochondriasis, and (2) to examine whether sin-
gle or combined pre-treatment variables were of prognos-
tic value and how strongly.
Methods
General Procedure and Setting
An inpatient treatment program for patients suffering from so-
matoform disorders and health anxieties was implemented and eval-
uated at the Roseneck Center for Behavioral Medicine, a research-
oriented hospital affiliated with the Medical Faculty of the Universi-
ty of Munich. Our approach was developed according to current
principles and techniques of CBT. In the present paper, we will focus
on patients diagnosed as hypochondriacal disorder or presenting
with a syndrome of health anxieties as measured by clinical rating
scales. A large number of sociodemographic and other pre-treatment
variables were assessed to serve as potential predictors. Patients com-
pleted a battery of self-rating scales focusing on psychopathology and
psychosocial impairments at baseline (pre-treatment), discharge
(post-treatment) and again at the two-year follow-up.
As a regular tertiary care hospital, the Roseneck Center is repre-
sentative for inpatient mental health treatment in Germany. It is
accessible to the general population, irrespective of social and voca-
tional status. Treatment indications cover all mental and psychophy-
siological disorders except schizophrenia and related psychotic disor-
ders, acute manic episodes, and severe disorders due to psychoactive
substances. As described in earlier studies [e.g., 8, 19], patients
referred to the Roseneck Center represent a high-risk group for so-
matoform disorders.
Sample Selection and Diagnostic Methods
Patients were consecutively selected if there was evidence of
unclear physical symptoms or health anxieties from the letters of the
referring clinicians, available medical records or the personal reports
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of the patients themselves. We excluded cases of primary eating dis-
orders or chronic tinnitus because these groups are treated in other
specialized departments. Based on these criteria, 324 patients were
selected for further diagnostic examination. They received a thor-
ough medical examination to rule out that the symptoms were due to
organic disease. In addition, other DSM-IV mental disorders were
systematically screened for to obtain a profile of comorbidity. We
performed detailed face-to-face interviews using the Structured Clin-
ical Interview (SCID) [22] and the International Diagnostic Check-
lists (IDCL) [23, 24]. Patients were included only after giving written
informed consent to participate in the study.
Defining Patients with Clinical Hypochondriasis
Of the 324 patients originally selected, 59 were found to meet the
DSM-IV criteria of current hypochondriacal disorder. Another 44
patients had high pre-treatment scores on two hypochondriasis
scales, the Illness Attitude Scales (IAS) and the Whiteley Index (WI).
The IAS was originally developed by Kellner [25, 26; see also 27]
and consists of 29 items which are to be rated on five-point Likert
scales. Although Kellner had originally defined nine a-priori scales
with three items per scale, a re-analysis reported by Speckens et al.
[21] and confirmed by us [28] suggests that two main dimensions
labeled ‘health anxieties’ and ‘illness behavior’ can be differentiated.
The WI is an internationally established short hypochondriasis scale
developed by Pilowsky [29]. We used a 10-item version for which
we demonstrated that maximum specificity and sensitivity against
the clinical DSM-IV diagnosis of hypochondriasis is reached. All
items of the WI were coded dichotomously (true-false). Based on
these questionnaires, we defined a clinically relevant syndrome of
hypochondriasis as a score of 643 on the IAS or 66 on the WI.
These cut-off values were derived from previous analyses as dis-
criminating best between hypochondriacal and non-hypochondria-
cal subjects [28].
Our hypochondriacal sample thus consisted of patients with
DSM-IV hypochondriacal disorder or high IAS/WI scores. The latter
patients missed the DSM-IV criteria mainly because they could not
name a specific feared disease (but were afraid that something unde-
fined was wrong with their body) or reported that their health anxie-
ties had not continuously persisted over at least 6 months. Their
DSM-IV comorbidity profile mainly included diagnoses of major
depression (84.1%), social phobia (38.6%), panic disorder (27.3%),
agoraphobia (22.7%) and substance use disorders (22.7%).
The Treatment Program
Treatment was interdisciplinary and followed the principles of
CBT and behavioral medicine. Patients received individual and
group psychotherapy at least once every day. As described by Bou-
man and Visser [13] or Warwick and Salkovskis [14], special atten-
tion was given to emotions, cognitions and behaviors related to bodi-
ly complaints and health anxieties. The main therapeutic techniques
included identification and modification of dysfunctional percep-
tions and thoughts. Longer-range goals were to increase self-care,
encourage physical activity, improve interpersonal and occupational
functioning, and lessen dependency on the medical care system. The
patients were also educated about the nature of their symptoms and
possible psychophysiological mechanisms relevant for the develop-
ment and maintenance of their complaints. Such techniques are part
of explanatory therapy, as developed by Kellner [30] and recently
evaluated by Fava et al. [31]. Pure medical consultations and medi-
cations were kept to a minimum to enhance the use of psychological
coping skills. When appropriate, we performed systematic physical
exercises with the patients in order to improve their bodily function-
ing and change their negative self-concept of being weak and dis-
abled. Other treatment components were assertiveness training, pro-
gressive relaxation and biofeedback sessions in which interactions
between physical and mental processes were demonstrated. All clini-
cians received concise treatment guidelines and a series of training
sessions. The complete program was summarized by us in a German
treatment manual [32].
Definition of Responders and Non-Responders
IAS and WI were used not only to assess the degree of hypochon-
driasis but also to define whether or not individual patients im-
proved during treatment. Patients were considered responders ac-
cording to two criteria: (1) improvement of at least 20% between
baseline and discharge on the total scores of the IAS or WI, or
(2) post-treatment IAS score ^20 or WI score ^3 (these scores indi-
cate the absence of clinically relevant hypochondriacal symptomatol-
ogy).
Based on these criteria, 58 patients (60.4%) were classified as
responders and 38 (39.6%) as non-responders. Seven patients from
the previously described hypochondriacal group could not be in-
cluded because of incomplete questionnaires at discharge. Our total
sample thus consisted of 96 patients. Their female proportion was
58.3% and their mean age 47.0 years (SD = 10.3) with a range
between 26 and 72 years. Further details about sociodemographic
and clinical characteristics will be given below. The mean treatment
length for the complete sample was 57.5 days (SD = 18.5) with no
significant difference between the responder and non-responder sub-
groups (t = 0.12, df = 94, p 1 0.05).
Predictor Variables
A broad list of personal, demographic, psychopathological and
psychosocial variables were assessed at pre-treatment.
Sociodemographic Characteristics. Age, sex, years of school or
academic education, and familial status were recorded for each
patient.
Pre-Treatment Measures of Psychopathology. We assessed the
degree of somatization, depression and general psychopathology by
means of self-rating scales: (1) the Screening for Somatoform Symp-
toms (SOMS), a validated index of medically unexplained physical
symptoms referring to the symptom lists of DSM-IV and ICD-10 (the
SOMS trait version gives the number of symptoms during the past
two years, the state version the number and degree of physical com-
plaints during the past seven days) [33]; (2) the Beck Depression
Inventory (BDI), a dimensional scale of depressive symptomatology
[34]; (3) the revised Symptom Checklist (SCL-90R), a widely used
instrument to assess general psychopathology with 90 items on nine
dimensions [35].
Pre-Treatment Cognitive Distortions. Based on a cognitive-behav-
ioral perspective, the Cognitions About Body and Health Question-
naire (CABAH) had been developed by Rief et al. [5] to assess proble-
matic cognitions and attitudes associated with bodily complaints,
extending and elaborating the 10-item Somatosensory Amplification
Scale proposed by Barsky et al. [36]. The CABAH used in our study
consists of 31 statements which define the following five subscales:
catastrophizing interpretation of bodily complaints, autonomic sen-
sations, bodily weakness, intolerance of bodily complaints, and
health habits.
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Comorbidity. Information about the presence or absence of any
additional DSM-IV axis I disorders was available from the detailed
standardized diagnostic interviews (see above).
Pre-Treatment Psychosocial Impairment. Our primary measure
to assess psychosocial functioning was the Dysfunctional Analysis
Questionnaire (DAQ) which had been employed in previous studies
with somatoform patients [8, 37]. The 45 items of the instrument can
be divided into five scales describing impairments in the following
areas: social, vocational, personal, familial, and cognitive. Each item
is rated on a five-point scale, comparing the present level of function-
ing with that before the onset of the disorder. We also interviewed
each patient on how many weeks she or he had been unable to work
during the past twelve months.
Chronicity. The number of years since onset of the disorder was
registered as based on the patients’ reports.
Pre-Treatment Use of Health Services. We assessed several mea-
sures related to health care utilization. Based on medical and billing
records of the patients’ health insurance companies, we re-calculated
expenditures made for outpatient and inpatient treatments as well as
costs for prescribed medications. These data refer to the two-year
period before treatment. In addition, the number of days spent in a
hospital during the past year was registered.
Statistics
Simple and multiple regression analysis were used to evaluate the
contribution of single variables and variable sets to predicting treat-
ment outcome. The strength of prediction is expressed by the amount
of variance of the criteria variable accounted for by the predictor
variables. The amount of explained (common) variance is equivalent
to squared correlation coefficients in simple regression (r2) and
squared multiple correlations in multiple regression (R2). Since we
also divided our sample into responders and non-responders, group
means were compared by Student’s t tests and proportions by ¯ 2 anal-
yses. Since not all data distributions were normal, we additionally
performed Mann-Whitney U tests. Because these yielded results sim-
ilar to those of the t tests, only the t values are reported here. The ·
significance level was conventionally set to 0.05.
Results
Comparison of Responders and Non-Responders
Table 1 shows that the degree of pre-treatment hypo-
chondriasis was significantly higher in non-responders in
the IAS (total score) but not in the WI. While no sociode-
mographic variables predicted group membership, non-
responders had significantly higher scores in the SOMS
(state version), SCL-90R, CABAH and DAQ. They also
reported a greater number of days not able to work in the
twelve-month period prior to treatment, had more ex-
penses for inpatient care and prescribed medication, and
spent more days in hospitals. Although substantial rates of
comorbid affective and anxiety disorder were found, nei-
ther the additional diagnoses of major depression nor
panic disorder were significant predictors (all other DSM-
IV mental disorders were also not predictive for treatment
response). Chronicity of the symptomatology was also not
different between both groups.
Relevance of Single Predictors
To estimate the strength of prediction, we calculated
how much variance of the dependent variables was ac-
counted for by the individual predicting variables (ta-
ble 2). Four criteria to be predicted were defined: (1) post-
treatment IAS scores, (2) short-term treatment effects on
the IAS as indicated by the difference between pre- and
post-treatment scores, (3) IAS scores at the two-year fol-
low-up examination, and (4) long-term treatment effects
on the IAS as indicated by the difference between pre-
treatment and two-year follow-up scores. Table 2 consid-
ers only variables which had differentiated in table 1
between the responder and non-responder groups. IAS
scores at post-treatment and follow-up were best pre-
dicted by pre-treatment IAS, SOMS-state, SCL-90R,
CABAH, DAQ and medication expenses. Inpatient treat-
ment costs and the number of days spent in hospitals pre-
dicted the patients’ condition at follow-up but not imme-
diately after treatment. Change during treatment was pre-
dicted only by CABAH and the disability to work, while
long-term changes were linked to pre-treatment IAS, SCL-
90R, inpatient treatment expenses and number of days
spent in hospitals. Interestingly, almost all correlations
with difference scores were negative, which means that
higher scores in the pre-treatment variable were associat-
ed with less improvement. The only exception are the IAS
scores which were positively related to outcome. It be-
comes evident from table 2 that the clinical status of the
patients at post-treatment and follow-up is generally bet-
ter predictable than improvements between two points of
measurement.
When predictors were analyzed on the level of sub-
scales, we found that patients with less catastrophizing
thinking (CABAH-I, 4.7% of variance explained, p !
0.05) and less health habits (CABAH-V, 7.0%, p ! 0.05)
improved stronger during treatment. The degree of occu-
pational impairments (DAQ-II, 4.9%, p ! 0.05) was also
negatively associated with treatment outcome (difference
scores). High scores on the SCL-90R subscale paranoid
ideation predicted less improvement between pre-treat-
ment and follow-up (6.9%, p ! 0.05). The original IAS
scales proposed by Kellner [25, 26] produced generally
weaker predictions than the factor analytically derived
IAS score used by us.
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Table 1. Comparison of responders and non-responders
Responders
(n = 58)
Non-responders
(n = 38)
Significance
Pre-treatment severity of hypochondriasis
IAS 51.4 (11.0) 57.4 (11.9) t = 2.52 (df = 94) p ! 0.01
WI 7.46 (1.80) 7.58 (1.75) t = 0.34 (df = 94) n.s.
Sociodemographic
Age 45.6 (9.3) 49.2 (11.5) t = 1.73 (df = 94) n.s.
Female 63.8% 50.0% ¯2 = 1.27 (df = 1) n.s.
Education ^ 9 years 55.2% 52.6% ¯2 = 0.01 (df = 1) n.s.
Married 60.3% 73.7% ¯2 = 1.27 (df = 1) n.s.
Divorced 6.9% 5.3% ¯2 = 0.00 (df = 1) n.s.
Pre-treatment measures of psychopathology
SOMS-trait 17.5 (7.2) 18.7 (8.9) t = 0.72 (df = 93) n.s.
SOMS-state 39.1 (25.4) 50.6 (27.6) t = 2.08 (df = 94) p ! 0.05
BDI 24.0 (10.2) 27.4 (9.2) t = 1.64 (df = 92) n.s.
SCL-90R (positive symptom total) 59.4 (18.1) 68.2 (13.8) t = 2.51 (df = 89) p ! 0.01
Pre-treatment cognitive distortions
CABAH 45.4 (13.3) 53.0 (11.8) t = 2.83 (df = 91) p ! 0.01
Comorbidity
Major depression 70.7% 84.2% ¯2 = 1.62 (df = 1) n.s.
Panic disorder 32.8% 23.7% ¯2 = 0.53 (df = 1) n.s.
Pre-treatment psychosocial impairment
DAQ 66.6 (14.7) 72.3 (13.6) t = 1.91 (df = 94) p ! 0.05
No. weeks not able to worka 11.8 (17.1) 21.5 (18.29) t = 2.32 (df = 72) p ! 0.05
Chronicity
No. years since onset 9.4 (9.2) 10.6 (9.8) t = 0.56 (df = 92) n.s.
Pre-treatment use of health services
Outpatient treatment expensesb 908 (920) 760 (503) t = 0.61 (df = 45) n.s.
Inpatient treatment expensesb 1,020 (1,887) 2,037 (3,229) t = 1.68 (df = 69) p ! 0.05
Medication expensesb 205 (246) 437 (460) t = 1.71 (df = 25) p ! 0.05
No. days in hospitalb 12.0 (23.1) 26.9 (38.3) t = 2.05 (df = 69) p ! 0.05
For continuous variables, means and standard deviations (in brackets) are displayed; for categorical variables,
percentage proportions are displayed. n.s. = Not significant in one-tailed tests.
a Refers to the twelve-month period before admission.
b Refers to the two-year period before admission, values are given in EUR.
Multiple Regression Analysis
To elucidate the combined predictive power of several
measures, multiple regression analysis with simultaneous
entry of variables was computed. We included only those
predictors that had been reported in table 2 as significant-
ly related to the individual criteria (only medication costs
were excluded because of the relatively small number of
cases for which these data were available). As can be seen
from table 3, the best overall predictions were obtained
for the IAS scores. 58.9% of the post-treatment and 41.4%
of the follow-up IAS variance were accounted for by the
entered variables. Improvements between pre- and post-
treatment (9.9%) and between pre-treatment and follow-
up (24.9%) were also predicted beyond statistical signifi-
cance, although these associations were clearly weaker.
Since pre-treatment severity of hypochondriasis pre-
dicted treatment response, it seemed necessary to repeat
the multiple regression analyses by controlling for pre-
treatment IAS scores. We therefore forced pre-treatment
IAS into the regression model as the first independent
variable and analyzed whether the remaining variables
still predicted significantly. 52.5% variance of the post-
treatment IAS scores were explained by pre-treatment
IAS alone and an additional proportion of 6.4% by the
other five predictors, which was only marginally signifi-
cant (F = 2.08, df = 5,67, p = 0.08). The relevance of pre-
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Table 2. Strength of prediction
Pre-treatment variables IAS score
post-treatment
IAS difference
pre- vs. post-
treatment
IAS score
2-year
follow-up
IAS difference
pre-treatment
vs. follow-up
IAS 52.5+,** !0.1 24.9+,** 6.1+,*
SOMS-state 9.8+, ** !0.1 10.9+,** 0.1
SCL-90R (positive symptom total) 9.0+, ** 0.8 17.3+,** 5.3–, *
CABAH 18.8+,** 6.3–, * 11.4+,** 1.0
DAQ 7.7+, ** 1.2 7.6+, * 0.6
Weeks not able to work 13.3+,** 6.6–, * 3.8 0.1
Inpatient treatment expenses (EUR) 1.0 0.1 10.1+,* 6.5–, *
Medication expenses (EUR) 18.0+,* 0.4 23.2+,* 0.8
No. days in hospital 0.9 !0.1 12.9+,** 7.8–, *
Strength of prediction is expressed as variance proportions, i.e. the amount of variance of the criterion variable
accounted for by the predicting variable. * p ! 0.05, ** p ! 0.01; it is additionally indicated for each significant
prediction whether the correlation between pre-treatment variable and predicted variable is positive (+) or nega-
tive (–).
Table 3. Results from multiple regression
analysis Predicted criteria
IAS score
post-treatment
IAS difference
pre- vs. post-
treatment
IAS score
2-year
follow-up
IAS difference
pre-treatment
vs. follow-up
Predictors 6 2 7 4
R2 0.589 0.099 0.414 0.249
Significance F = 16.0**
df = 6,67
F = 3.88*
df = 2,71
F = 5.36**
df = 7,61
F = 4.63**
df = 4,56
* p ! 0.05; ** p ! 0.01.
treatment hypochondriasis was clearly smaller for the fol-
low-up period. 16.5% of the follow-up IAS scores (F =
2.50, df = 6,54, p ! 0.05) and 18.8% of the change
between baseline and follow-up (F = 4.66, df = 3,57, p !
0.01) were explained independently from the pre-treat-
ment IAS scores.
Discussion
Although CBT is known to be generally effective for
patients suffering from unclear medical symptoms and
health anxieties, not all patients respond to treatment or
reach clinically relevant improvements. We have there-
fore conducted a prospective study aiming at identifying
prognostic factors for treatment response. CBT was ap-
plied to hypochondriacal inpatients in a natural clinical
setting and a large number of potential predictors were
assessed prior to treatment. Outcome was then evaluated
immediately after the end of the treatment and once more
two years later. Because almost nothing is known from the
existing literature about predictors of treated hypochon-
driasis, the primary aim of our study was not to test the
hypothesized predictive value of specific variables but
rather to search for baseline conditions explaining the out-
come and further course of the disorder.
About 60% of our patients reached considerable im-
provements or were no longer hypochondriacal after
treatment. Responders and non-responders could be dif-
ferentiated on several baseline variables. Non-responders
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were more hypochondriacal, had more somatization
symptoms and general psychopathology, reported more
dysfunctional cognitions related to their bodily function-
ing, had higher levels of psychosocial and work disability,
and showed an increased pattern of health care utilization
with more days of hospital treatment and higher inpatient
and medication expenses. Most of these variables pre-
dicted, independently from each other, the degree of hy-
pochondriasis at post-treatment and follow-up. Multiple
regression analysis showed that the combined predictors
explained 58.9% of IAS variance at post-treatment and
41.4% of IAS variance at follow-up. It is worth noting that
sociodemographic factors, comorbidity and chronicity
were no significant predictors.
A second result from our study is that changes occur-
ring during treatment or between baseline and follow-up
were less strongly predictable. However, dysfunctional
cognitions as well as work disabilities were significantly
associated with direct treatment effects, each variable
explaining about 6% of variance. Higher degrees of distur-
bance in both variables were associated with less improve-
ment. The long-term changes between baseline and fol-
low-up were linked to pre-treatment hypochondriasis,
psychopathology, inpatient costs and days in hospital. If
combined, these four variables accounted for about 25%
of the variance. Thus, a substantial degree of the patients’
course during the follow-up period could be predicted
from pre-treatment characteristics. The results also indi-
cate that patients with lower degrees of psychopathology
or psychosocial impairments develop better during or
after treatment. The severity of the disorder is therefore a
clear negative predictor for treatment outcome. This find-
ing corresponds to research in other areas showing that
treatment effects for many other mental disorders seem to
be generally more favorable in patients with relatively
moderate symptomatology (e.g., for depressive disorder
see Sotsky et al. [38]).
Although this study represents a first step to identify
predictors for hypochondriasis, some methodological lim-
itations should be mentioned. First, our sample was
drawn from an inpatient population which may differ
from outpatients with respect to the severity and chronici-
ty of symptomatology. Second, since not all patients ful-
filled the strict DSM-IV criteria of hypochondriasis, the
nature of our sample is likely to be somewhat more het-
erogeneous than according to usual clinical classification.
Third, the response criterion of 20% improvement was
chosen rather arbitrarily and a lower proportion of re-
sponders would have been identified using a more re-
strictive criterion (for example, 30.2% of the sample
achieved a 50% reduction). Our results can therefore be
interpreted as including both patients with complete as
well as partial remission (incomplete recovery). Fourth,
while our patients received daily intense treatment with
multiple components, usual outpatient CBT is limited to
one weekly session and only one therapist is involved. It is
possible that a different pattern of predictors would be
found in other settings. We wish to emphasize that
although our treatments were not strictly standardized
with respect to duration and contents, prognostic factors
were evaluated under the naturalistic conditions of a regu-
lar health care setting. Other strengths of the present study
are the relatively large sample size, the assessment of var-
ious hypochondriasis-related variables and the long fol-
low-up period.
Special efforts should be made to distinguish the natu-
ral course of hypochondriacal disorder from the course
influenced by treatment, although such research is often
difficult for methodological and ethical reasons. An early
study of treated hypochondriasis, employing explanatory
psychotherapy as well as medication, was conducted by
Kellner [30] with the result that favorable outcome two
years later was associated with shorter illness duration
and absence of personality disorder. Only a few naturalis-
tic studies have used a prospective design to re-assess
hypochondriacal patients after longer periods of time [12,
39–42]. One major problem of these studies is that treat-
ment between inception and follow-up was not systemati-
cally controlled for. Untreated patients were not distin-
guished from patients who had received different treat-
ments of different intensities. However, these studies
have tentatively indicated the existence of some general
prognostic factors. For example, better outcome seems to
be associated with less medical morbidity and less comor-
bid major depressive and anxiety disorders at inception
[12], shorter duration of hypochondriasis, lower neuroti-
cism scores and the demographic variables of being em-
ployed and married [39], and with a less pathological
combination of somatization, amplification of bodily sen-
sations and attribution of symptoms to disease [40, 41].
Most of these factors have not been confirmed consistent-
ly enough and therefore do not yet constitute a compre-
hensive model.
To summarize, the present study has shown that
response to CBT and further development of hypochon-
driacal patients in the two years following treatment can
be predicted significantly by a number of pre-treatment
variables. The strongest predictors were dysfunctional
cognitions and disability at work for short-term treatment
effects, and the degree of pre-treatment hypochondriasis,
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general psychopathology, inpatient treatment costs and
days in hospital for effects in the follow-up period. These
results may enhance the ability of the clinician to make a
more realistic prognosis about expected treatment out-
comes.
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